EyePoint Pharmaceuticals's total assets for Q3 2025 were $251.69M, a decrease of -16.42% from the previous quarter. EYPT total liabilities were $51.51M for the fiscal quarter, a -6.57% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.